FDA OKs Novel Levodopa-Based Regimen for Parkinson’s 🔗 Access full article via Medscape NeurologyVyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease. Medscape Medical News Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
